Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Simeprevir will be supplied as 75 and 150 mg oral capsules.

Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

TMC647055 will be supplied as 150 mg oral capsules.

Ritonavir will be supplied as 80 mg/mL oral solution.

Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.